• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病性黄斑水肿和渗出性黄斑变性患者的预约依从性

Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration.

作者信息

Jansen Michael E, Krambeer Chelsey J, Kermany Daniel S, Waters Jana N, Tie Wayne, Bahadorani Sepehr, Singer Julia, Comstock Jordan M, Wannamaker Kendall W, Singer Michael A

出版信息

Ophthalmic Surg Lasers Imaging Retina. 2018 Mar 1;49(3):186-190. doi: 10.3928/23258160-20180221-06.

DOI:10.3928/23258160-20180221-06
PMID:29554386
Abstract

BACKGROUND AND OBJECTIVE

The purpose of this study is to compare cancellation and no-show rates in patients with diabetic macular edema (DME) and exudative macular degeneration (wet AMD).

PATIENTS AND METHODS

An anonymous survey was sent to 1,726 retina specialists inquiring as to the number of appointments their patients with DME and wet AMD attended, cancelled, or did not show up for in 2014 and 2015.

RESULTS

Data were obtained on 109,599 appointments. Patients with DME in the U.S. had a 1.591-times increased odds of cancelling or no-showing to their appointments than patients with wet AMD (P < .0001). Patients with DME in Europe had a 1.918-times increased odds of cancelling or no showing to their appointments than patients with wet AMD (P < .0001).

CONCLUSION

Patients with DME in the U.S. and Europe cancelled and no-showed to their appointments significantly more often than patients with wet AMD. These findings can be taken into consideration when establishing treatment plans for patients with DME. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:186-190.].

摘要

背景与目的

本研究旨在比较糖尿病性黄斑水肿(DME)患者和渗出性黄斑变性(湿性年龄相关性黄斑变性,wet AMD)患者的预约取消率和爽约率。

患者与方法

向1726名视网膜专家发送了一份匿名调查问卷,询问他们的DME和湿性AMD患者在2014年和2015年就诊、取消预约或爽约的次数。

结果

共获得了109599次预约的数据。美国的DME患者取消或爽约预约的几率比湿性AMD患者高1.591倍(P <.0001)。欧洲的DME患者取消或爽约预约的几率比湿性AMD患者高1.918倍(P <.0001)。

结论

美国和欧洲的DME患者取消和爽约预约的情况明显比湿性AMD患者更频繁。在为DME患者制定治疗计划时可考虑这些发现。[《眼科手术、激光与视网膜成像》。2018;49:186 - 190。]

相似文献

1
Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration.糖尿病性黄斑水肿和渗出性黄斑变性患者的预约依从性
Ophthalmic Surg Lasers Imaging Retina. 2018 Mar 1;49(3):186-190. doi: 10.3928/23258160-20180221-06.
2
COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.糖尿病性黄斑水肿患者在日常实践中接受玻璃体内抗血管内皮生长因子治疗的依从性和顺应性。
Retina. 2018 Dec;38(12):2293-2300. doi: 10.1097/IAE.0000000000001892.
3
Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea.在年龄相关性黄斑变性和糖尿病性黄斑水肿中,对贝伐单抗药物治疗反应不佳者出现阻塞性睡眠呼吸暂停的风险增加。
Retina. 2014 Dec;34(12):2423-30. doi: 10.1097/IAE.0000000000000247.
4
Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities.量化糖尿病性黄斑水肿及其他黄斑异常患者的视物变形
Acta Ophthalmol. 2015 Dec;93(8):e649-53. doi: 10.1111/aos.12735. Epub 2015 Apr 20.
5
QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.定量光学相干断层扫描分析糖尿病性黄斑水肿和新生血管性年龄相关性黄斑变性的视网膜退行性变化。
Retina. 2018 Jul;38(7):1324-1330. doi: 10.1097/IAE.0000000000001696.
6
Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.视网膜疾病抗血管内皮生长因子治疗期间视力与视网膜厚度的关系
Am J Ophthalmol. 2017 Aug;180:8-17. doi: 10.1016/j.ajo.2017.05.014. Epub 2017 May 24.
7
Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles.糖尿病性黄斑水肿对视盘周围视网膜神经纤维层厚度曲线的影响。
Invest Ophthalmol Vis Sci. 2014 May 15;55(7):4213-9. doi: 10.1167/iovs.13-13776.
8
Real-World Use of Off-Label MVASI in the Treatment of Patients With Neovascular AMD and DME.真实世界中使用 MVASI 药物治疗新生血管性 AMD 和 DME 患者。
Transl Vis Sci Technol. 2024 Jul 1;13(7):17. doi: 10.1167/tvst.13.7.17.
9
Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel.皮质类固醇在抗VEGF治疗反应欠佳的糖尿病性黄斑水肿患者治疗中的应用:专家小组建议
Ophthalmic Surg Lasers Imaging Retina. 2017 Apr 1;48(4):291-301. doi: 10.3928/23258160-20170329-03.
10
Ziv-aflibercept in macular disease.阿柏西普用于黄斑疾病
Br J Ophthalmol. 2015 Aug;99(8):1055-9. doi: 10.1136/bjophthalmol-2014-306319. Epub 2015 Feb 12.

引用本文的文献

1
Treatment Cessation in Patients with Diabetic Maculopathy under Intravitreal Anti-VEGF Therapy Following a Treat-and-Extend Protocol.遵循“治疗并延长”方案的玻璃体腔抗VEGF治疗的糖尿病性黄斑病变患者的治疗终止情况
Ophthalmol Sci. 2025 Jun 2;5(6):100838. doi: 10.1016/j.xops.2025.100838. eCollection 2025 Nov-Dec.
2
Predictors of Vision Loss After Lapse in Antivascular Endothelial Growth Factor Treatment in Patients With Diabetic Macular Edema.糖尿病性黄斑水肿患者抗血管内皮生长因子治疗中断后视力丧失的预测因素
J Vitreoretin Dis. 2024 Dec 13:24741264241305123. doi: 10.1177/24741264241305123.
3
Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology.
抗血管内皮生长因子治疗糖尿病性黄斑水肿的长期管理:基于黄斑形态的靶向治疗策略。
Graefes Arch Clin Exp Ophthalmol. 2024 Dec;262(12):3749-3759. doi: 10.1007/s00417-024-06558-y. Epub 2024 Jul 12.
4
Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema.在初治和治疗难治性糖尿病性黄斑水肿患者中,布罗鲁单抗与阿柏西普对比的真实世界经验。
J Clin Med. 2024 Mar 21;13(6):1819. doi: 10.3390/jcm13061819.
5
Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab.接受布罗利珠单抗治疗的糖尿病性黄斑水肿(DME)患者停药后疾病的持续控制情况。
J Clin Med. 2024 Mar 7;13(6):1534. doi: 10.3390/jcm13061534.
6
Intravitreal DEX Implant for the Treatment of Diabetic Macular Edema: A Review of National Consensus.玻璃体内地塞米松植入物治疗糖尿病性黄斑水肿:一项全国性共识综述
Pharmaceutics. 2023 Oct 13;15(10):2461. doi: 10.3390/pharmaceutics15102461.
7
Compliance with follow-up in patients with diabetic macular edema: Eye care center vs. diabetes care center.糖尿病性黄斑水肿患者的随访依从性:眼科中心与糖尿病护理中心。
Indian J Ophthalmol. 2023 Jun;71(6):2531-2536. doi: 10.4103/IJO.IJO_220_23.
8
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries.糖尿病性黄斑水肿抗VEGF治疗的真实世界结果:治疗成功的障碍及对低收入/中低收入国家的影响
Ophthalmol Ther. 2023 Apr;12(2):809-826. doi: 10.1007/s40123-023-00672-6. Epub 2023 Feb 23.
9
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects.布罗鲁单抗治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿:眼科和糖尿病学治疗方面
Ophthalmol Ther. 2023 Apr;12(2):639-655. doi: 10.1007/s40123-023-00647-7. Epub 2023 Jan 12.
10
Racial, Ethnic, and Socioeconomic Disparities Drive Appointment No-Show in Patients with Chronic Eye Disease.种族、民族和社会经济差异导致慢性眼病患者预约失约。
J Racial Ethn Health Disparities. 2023 Aug;10(4):1790-1797. doi: 10.1007/s40615-022-01363-x. Epub 2022 Jul 21.